Last updated: August 7, 2026
Up & Up Nighttime Sleep Aid is a private-label over-the-counter sleep product whose commercial value depends more on cost-efficient formulation, tablet performance, packaging, and retail differentiation than on drug-substance exclusivity. The likely active ingredient is either doxylamine succinate 25 mg or diphenhydramine hydrochloride 25 mg, depending on the specific Up & Up SKU. These products are generally regulated under FDA OTC monograph conditions for nighttime sleep aids rather than through a new-drug approval pathway.[1]
The most attractive excipient opportunities are improved swallowability, faster but controlled disintegration, moisture protection, differentiated dosage forms, and formulations that support premium pricing without changing the active ingredient.
What active ingredient is in Up & Up Nighttime Sleep Aid?
Up & Up has marketed nighttime sleep-aid products using first-generation antihistamines. The two relevant active ingredients are doxylamine succinate and diphenhydramine hydrochloride.
| Product type |
Typical active ingredient |
Common OTC strength |
Commercial positioning |
| Nighttime sleep aid tablets or caplets |
Doxylamine succinate |
25 mg |
Longer-duration sleep aid |
| Nighttime sleep aid tablets or caplets |
Diphenhydramine HCl |
25 mg |
Broadly recognized antihistamine sleep aid |
| Nighttime liquid sleep aid |
Diphenhydramine HCl or combination ingredients |
Label-specific |
Easier administration and family-oriented packaging |
The exact excipient strategy must be tied to the National Drug Code, dosage form, and current product label. Up & Up is a Target private-label brand, and formulations may change across suppliers, package sizes, and manufacturing periods.
Under FDA regulations, doxylamine succinate and diphenhydramine hydrochloride are recognized OTC nighttime sleep-aid actives when labeled and used under applicable monograph conditions.[1] The products are not biologics, so biosimilar risk is not relevant. Competitive risk comes from generic and private-label substitution, retailer switching, and branded alternatives such as Unisom and Benadryl.
What excipients are likely used in Up & Up Nighttime Sleep Aid tablets?
Public product labeling identifies the active ingredient but does not always disclose the complete qualitative and quantitative excipient formula. Typical immediate-release antihistamine caplets use a conventional platform built around a filler, binder, disintegrant, lubricant, glidant, and film-coating system.
Potential excipient classes include:
| Functional role |
Common excipient options |
Strategic purpose |
| Diluent or filler |
Microcrystalline cellulose, dibasic calcium phosphate, lactose, starch |
Controls tablet weight, hardness, and cost |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Improves granule and tablet cohesion |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Promotes tablet breakup after ingestion |
| Lubricant |
Magnesium stearate, stearic acid, sodium stearyl fumarate |
Supports compression and ejection |
| Glidant |
Colloidal silicon dioxide, talc |
Improves powder flow |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, colorants |
Controls appearance, handling, and swallowability |
| Opacifier or colorant |
Titanium dioxide alternatives, iron oxides, approved dyes |
Supports brand identification and visual differentiation |
A standard tablet formula offers limited patent protection because the excipients are common and the product is likely manufactured under an OTC pathway. The commercial objective is therefore formulation robustness and cost control rather than exclusivity through a novel composition.
How should excipients be selected for a private-label sleep-aid tablet?
The optimal formulation should balance low cost with reliable performance across high-volume manufacturing. The main technical risks are poor powder flow, tablet capping, excessive hardness, slow disintegration, sticking during compression, and moisture-driven degradation or dissolution changes.
Disintegration and dissolution
Immediate-release sleep-aid tablets should disintegrate consistently without creating an excessively fragile tablet. Croscarmellose sodium, crospovidone, and sodium starch glycolate are established choices, but their performance depends on concentration, granulation method, compression force, and lubricant exposure.
Crospovidone may support rapid liquid uptake and is often useful where a formulation requires fast breakup without substantial swelling. Croscarmellose sodium can provide strong wicking and swelling performance. Sodium starch glycolate may be cost-effective but can produce variable performance if overused or exposed to high moisture.
For a private-label product, the preferred approach is usually a robust disintegrant system rather than a highly complex excipient architecture. The formulation should meet dissolution and dosage-unit requirements across the commercial shelf life, including after accelerated stability testing.
Tablet size and swallowability
Doxylamine and diphenhydramine sleep-aid tablets are often taken shortly before bedtime. A large, hard caplet can create a poor user experience, particularly for older consumers and patients with dysphagia.
Excipient-driven size reduction can create a commercial advantage. High-functionality microcrystalline cellulose, spray-dried mannitol, and direct-compression excipients can reduce tablet weight or improve compressibility. A smaller caplet, smooth film coating, and rounded tablet geometry may support premium positioning without changing the active ingredient.
Taste and mouthfeel
Taste masking is less important for conventional swallowed tablets than for liquids, chewables, or orally disintegrating tablets. It becomes important if Up & Up expands into a fast-dissolve or chewable format.
Potential taste-masking tools include:
- Polymer coating of the active ingredient
- Ion-exchange resin complexes
- Flavored sugar or polyol matrices
- Lipid barriers
- High-intensity sweetener systems
- Microencapsulation
Doxylamine and diphenhydramine can have an unpleasant taste profile. A chewable or orally disintegrating product would require more sophisticated taste masking than a standard caplet and would carry greater development and stability risk.
Moisture protection
Moisture control is a meaningful opportunity because many disintegrants and direct-compression excipients are hygroscopic or moisture-sensitive. Packaging can be as important as the excipient formula.
Options include:
- High-barrier HDPE bottles
- Induction seals
- Desiccant canisters
- Blister packaging with high-barrier foil
- Unit-dose pouches
- Moisture-resistant film coatings
A blister format may support portability and dosage control, while a bottle generally offers lower packaging cost for high-volume retail. A premium sleep-aid line could use unit-dose blister packs to support travel and reduce accidental exposure.
What formulation patents protect Up & Up Nighttime Sleep Aid?
No patent-based exclusivity should be assumed for a conventional Up & Up doxylamine or diphenhydramine tablet. The relevant product is likely an OTC monograph product, and the active ingredients are longstanding generic compounds.
The principal IP categories that could affect a competing formulation are:
- Specific dosage-form patents. These could cover orally disintegrating tablets, chewables, liquid gels, or extended-release systems.
- Taste-masking patents. These may cover coated particles, resin complexes, or specific polymer systems.
- Manufacturing patents. These may cover direct compression, granulation, coating, or multiparticulate processing.
- Packaging patents. These could cover child-resistant, unit-dose, or moisture-control systems.
- Trade dress and trademarks. These are more relevant to a private-label retailer than composition patents.
A conventional immediate-release caplet made with standard excipients is unlikely to create a strong blocking patent position. Any potentially valuable formulation patent would need to claim a measurable technical improvement, such as improved stability, reduced tablet size, faster disintegration, reduced taste, or a differentiated release profile.
What is the FDA regulatory status of Up & Up Nighttime Sleep Aid?
Nighttime sleep aids containing doxylamine succinate or diphenhydramine hydrochloride are generally regulated as OTC products under FDA requirements for internal analgesic, antipyretic, and antirheumatic products and nighttime sleep-aid labeling, depending on the active ingredient and product claims.[1]
Key regulatory considerations include:
| Regulatory issue |
Commercial implication |
| OTC monograph compliance |
Reduces need for a conventional NDA |
| Drug Facts labeling |
Limits claims and determines warnings |
| Active-ingredient concentration |
Must remain within permitted OTC conditions |
| Inactive ingredients |
Must be suitable for oral use and supported by quality controls |
| Child-resistant packaging |
Relevant to household products containing sedating antihistamines |
| Stability and dissolution |
Required to support shelf life and batch release |
| Manufacturing controls |
Must comply with current good manufacturing practice |
| Labeling changes |
May require retailer and regulatory coordination |
The product cannot be positioned as treating insomnia or a chronic sleep disorder without creating a different regulatory risk profile. Claims should remain within permitted temporary-relief and nighttime-sleep-aid language.
Does Up & Up Nighttime Sleep Aid have Orange Book or Paragraph IV risk?
The Orange Book and Paragraph IV framework primarily applies to approved prescription and certain approved nonprescription drug products. A conventional OTC monograph product does not ordinarily create the same Orange Book patent-listing profile as an NDA product.
For a generic or private-label competitor, the principal launch risks are therefore:
- Failure to comply with the applicable OTC monograph
- Drug Facts labeling differences
- Manufacturing-site qualification
- Supplier changes affecting dissolution
- Trademark or trade-dress disputes
- Product liability exposure
- Retailer qualification and supply continuity
A Paragraph IV challenge is generally not the central commercial pathway for a standard Up & Up nighttime sleep-aid tablet. A competitor would more likely enter by developing a monograph-compliant product and obtaining its own NDC rather than challenging a branded patent estate.
What excipient strategies create the strongest commercial opportunities?
1. Smaller, easier-to-swallow caplets
A compact caplet using high-functionality fillers and optimized compression could improve patient acceptance. The opportunity is strongest for older consumers and repeat users who take the product frequently.
2. Rapid-disintegrating tablets
A faster-disintegrating tablet can support a "quick dissolve" or "easy-to-take" positioning, subject to substantiation and compliant labeling. The formulation must not imply faster onset of pharmacologic action unless supported by appropriate evidence.
3. Liquid gels
Liquid-filled softgels can improve swallowing and provide a premium appearance. They require greater manufacturing complexity, shell compatibility testing, fill-volume control, and oxygen and moisture evaluation. A liquid-gel product may command a higher retail price than a basic caplet but is more exposed to supply-chain and quality costs.
4. Unit-dose travel packaging
A blister-packed nighttime sleep aid can be positioned for travel, hotels, and occasional use. The key value is packaging convenience rather than a new drug effect. High-barrier materials can also reduce moisture risk.
5. Alcohol-free liquid formulations
An alcohol-free liquid could serve consumers who avoid ethanol-containing products or have difficulty swallowing tablets. The main excipient challenges are solubilization, preservative efficacy, flavor masking, viscosity, pH control, and microbial stability.
6. Lower-excipient and allergen-conscious formulations
A formulation excluding lactose, gluten-derived materials, artificial colors, or selected preservatives may support retailer segmentation. These claims must be accurate and supported by supplier controls. "Free-from" positioning can increase complexity if excipient suppliers change.
7. Sustainable packaging
Reducing plastic weight, using recyclable components, and replacing unnecessary secondary packaging may reduce cost and support retailer sustainability goals. Packaging changes must preserve child resistance, moisture protection, tamper evidence, and shelf life.
How does the excipient opportunity compare with branded sleep-aid products?
| Attribute |
Up & Up conventional tablet |
Branded antihistamine tablet |
Premium differentiated product |
| Active ingredient |
Generic doxylamine or diphenhydramine |
Same or comparable active |
Same active or modified dosage form |
| Core excipients |
Standard, low-cost platform |
Standard with brand-specific appearance |
Higher-functionality and taste-masking systems |
| Patent strength |
Usually low |
Usually low for legacy actives |
Potentially moderate if technically novel |
| Price position |
Value |
Mid-market |
Premium |
| Main advantage |
Retail price and availability |
Brand recognition |
Convenience and user experience |
| Main risk |
Margin compression |
Substitution by private label |
Development and regulatory cost |
The strongest opportunity is not to out-license a novel excipient platform. It is to create a differentiated private-label product that improves convenience while retaining a low manufacturing cost.
What manufacturing and IP barriers affect commercial entry?
Manufacturing barriers are moderate for tablets and higher for liquids, softgels, and orally disintegrating formats.
A conventional caplet requires standard equipment and widely available excipients. The main barriers are process validation, dissolution control, supplier qualification, and retailer quality requirements. A softgel or taste-masked dosage form requires specialized equipment and may introduce patent exposure from third-party delivery-system technologies.
The most defensible IP strategy would focus on a narrow, evidence-backed formulation claim, such as:
- A specific low-weight tablet with defined hardness and disintegration
- A moisture-stable formulation with a defined impurity profile
- A taste-masked multiparticulate system
- A unit-dose package with validated stability and child resistance
- A manufacturing process that improves content uniformity or throughput
Broad claims covering ordinary use of microcrystalline cellulose, magnesium stearate, or common superdisintegrants would have limited strength because of extensive prior art.
What is the revenue exposure and competitive outlook?
Up & Up Nighttime Sleep Aid competes in a high-volume, low-differentiation OTC category. Revenue is exposed to:
- Retailer shelf placement
- Target private-label pricing
- Seasonal demand
- Consumer switching between doxylamine and diphenhydramine
- Supply interruptions
- Class-wide safety concerns regarding sedating antihistamines
- Competition from melatonin, magnesium, herbal products, and behavioral sleep solutions
A basic tablet is likely to generate volume but limited gross-margin expansion. Premium excipient and packaging changes can improve margin if they produce a clear consumer benefit and do not materially increase manufacturing cost.
The most attractive commercial sequence is:
- Optimize the existing caplet for size, hardness, disintegration, and stability.
- Introduce travel blister packaging.
- Test a premium liquid-gel or fast-dissolve extension.
- Use retailer-specific packaging and price architecture.
- Protect any genuinely novel dosage form through formulation and manufacturing patents.
Key Takeaways
- Up & Up Nighttime Sleep Aid is likely a doxylamine succinate or diphenhydramine hydrochloride OTC product, depending on the SKU.
- Standard tablet excipients offer manufacturing value but limited standalone IP protection.
- The strongest formulation opportunities are swallowability, rapid disintegration, moisture stability, taste masking, and unit-dose packaging.
- FDA OTC monograph compliance, not NDA patent litigation, is likely to control market entry.
- Paragraph IV risk and Orange Book exposure are generally limited for a conventional OTC monograph product.
- Premium commercial opportunities are more likely in liquid gels, orally disintegrating formats, alcohol-free liquids, and travel packaging.
- A defensible patent position would require a specific technical improvement rather than routine use of common excipients.
- Retail execution, price, supply reliability, and consumer convenience are likely to matter more than active-ingredient exclusivity.
FAQs About Up & Up Nighttime Sleep Aid Excipients and Commercial Strategy
Can a competitor legally copy the excipients in Up & Up Nighttime Sleep Aid?
A competitor can generally use the same common excipients if its product complies with FDA requirements and does not infringe an enforceable formulation or manufacturing patent. Trademark, trade dress, and confidential manufacturing information remain separate risks.
Which dosage form offers the best premium opportunity?
Liquid gels and orally disintegrating tablets offer the clearest premium positioning, but they also carry higher formulation, manufacturing, and stability costs. Travel blister packaging may provide the best cost-to-differentiation ratio.
Are doxylamine and diphenhydramine interchangeable in a private-label product?
They are not interchangeable from a regulatory, labeling, clinical, or consumer-use perspective. Each active ingredient requires its own compliant Drug Facts labeling, warnings, dosage instructions, and product qualification.
Can excipients support a faster-onset sleep-aid claim?
Excipient-driven disintegration can improve tablet performance, but it does not automatically establish faster pharmacologic onset. Any onset claim requires appropriate evidence and must comply with FDA labeling requirements.
What is the strongest IP strategy for a new nighttime sleep-aid formulation?
The strongest strategy is a narrowly defined patent covering a measurable technical benefit, such as improved stability, taste masking, tablet miniaturization, rapid disintegration, or a specialized delivery system.
References
-
U.S. Food and Drug Administration. (2024). Electronic Code of Federal Regulations, Title 21, Part 329: Nonprescription drugs generally recognized as safe and effective. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-329
-
U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
-
U.S. Food and Drug Administration. (2024). Drug Facts labeling for nonprescription drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/drug-facts-labeling
-
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm
